Fast food nation! The title compound (pictured) was identified as a potential peripheral CB1-acting antagonist based on its negative central effects in CB1R agonist-induced hypothermia and analgesia models, and low brain exposure as indicated by the blood-to-plasma ratio. This compound represents a potential lead in the treatment of metabolic disorders.
